AAV-mediated gene therapy for dysferlinopathy involves introducing functional copies of the dysferlin gene into affected cells to compensate for the defective or absent dysferlin protein. The gene discussed is DYSF; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.